Taiwan FDA registration 064d68cbec26a09925da22a963b1e7f2
LiRAS for LiPA HLA
TW: 立帕人類白血球抗原分析軟體
Taiwan·Risk Class 2·MD·FUJIREBIO EUROPE N.V.·Registered May 13, 2016 – May 13, 2026CancelledRegistration details
- Analysis ID
- 064d68cbec26a09925da22a963b1e7f2
- License Form
- Ministry of Health Medical Device Import No. 028424
- Customs Code
- DHA05602842409
Company information
- Manufacturer
- FUJIREBIO EUROPE N.V.
- Manufacturer Country
- Belgium
- Authorized Representative
- Taiwan Fu Pharmaceutical Co., Ltd
Product details
- Product Type (Level 1)
- B Hematology and pathology devices
- Product Type (Level 2)
- B0001 Human leukocyte antigen segmentation board
- Import Information
- Imported from abroad
Dates and status
- Registration Date
- May 13, 2016
- Expiry Date
- May 13, 2026
- Cancellation Date
- Oct 28, 2022
Cancellation information
- Status
- Logged out
- Reason
- 公司歇業
About this record
Access comprehensive regulatory information for LiRAS for LiPA HLA in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 064d68cbec26a09925da22a963b1e7f2 and manufactured by FUJIREBIO EUROPE N.V.. The authorized representative in Taiwan is Taiwan Fu Pharmaceutical Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices